Tag Archives: FDA

On May 23, 2017, Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced that it’s poised to present data from its lead cystic fibrosis (CF) study at the upcoming European Cystic Fibrosis Society Conference. On the back of the news, the...

Back on May 10, we published this piece asking the question: Is The Elite Pharmaceuticals Inc (OTCMKTS:ELTP) Data About To Hit Press? The data we were referring to was from a bioequivalent study of its lead development outside, an abuse-deterrent...

Pulmatrix Inc (NASDAQ:PULM) reported earlier this month that it has picked up an additional patent related to its lead development program – PUR0200 in chronic obstructive pulmonary disease (COPD). It adds to a list of a number of already...

Neovasc Inc (US) (NASDAQ:NVCN) just put out its first-quarter earnings, and the company has taken a bit of a hit on the release. At last close, shares went for $1.43 a piece – a more than 15% decline on the company’s prerelease pricing....

Neuralstem, Inc. (NASDAQ:CUR) is one of those biotechnology stocks that can be tough to hold. The company effected a reverse split back in January, bringing its post-split price to a little over six dollars a share. Subsequent to this point,...

RenovaCare Inc (OTCMKTS:RCAR) has been a roller coaster of a stock across the last six months. The company went for less than a dollar a share as recently as November 2016, before hitting highs of $5.5 a share mid-February. This more than 450%...

Viaderma Inc (OTCMKTS:VDRM) took a bit of a hit recently based on the surfacing of some litigation related to the delivery method associated with its lead asset. Over the last few days, however, the company has recovered much of the lost ground,...

We’ve covered GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) twice during the last eight months. The first was back in October, when the company was trading at $117 a share. The second was at the end of February, at which point GW Pharmaceuticals...

We have been waiting patiently for development stage biotechnology company Elite Pharmaceuticals Inc (OTCMKTS:ELTP) to validate our long-term bull thesis for the last 10-12 months. The company took a hit last year when the FDA rejected its...

Development stage biotechnology company Nemus Bioscience Inc (OTCMKTS:NMUS) just announced that it raised $20 million by way of series E preferred stock financing, and the company has taken a bit of a hit on the back of the news. From its May...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter